Joint Formulary & PAD

Ustekinumab - Psoriasis

You are here : Home > Formulary Search > Ustekinumab - Psoriasis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
ICB
NICE
SPC
Restrictions / Comments :

Documentation

NICE Technology Appraisal
NICE TA180 - Ustekinumab for treating Psoriasis

PAD Profile

ChemicalSubstance :
Ustekinumab
Indication :
Psoriasis
Group Name :
Keywords :
Biologic, interleukin 23 (IL-23) protein, Dermatology, plaque psoriasis, monoclonal antibody, cytokine modulator, immunosuppression
Brand Names Include :
Stelara, Uzpruvo, Pyzchiva, Wezenla, Steqeyma, Imuldosa
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Psoriasis
Supporting Documents :
1

Committee Recommendations (1)

05 Nov 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartland Integrated Care System Area Prescribing Committee have agreed to adopt the SERMOG high-cost drugs pathway.for adiults with psoriasis

Other Indications

Below are listed other indications that Ustekinumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Psoriasis.